At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
5x5cm bupivacaine collagen spongesdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Single-dose, Open-label Study to Investigate the Feasibility and Efficacy of the CollaRx® Bupivacaine Implant (200 mg Bupivacaine Hydrochloride) in Men After Laparoscopic Inguinal or Umbilical Herniorrhaphy
In Brief
A Phase 2 clinical trial evaluating 5x5cm bupivacaine collagen sponges for Hernia and Postoperative Pain. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This study will assess pain intensity for the first 72 hrs after aggravated movement (cough) following Laparoscopic Inguinal or Umbilical Herniorrhaphy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHernia, Postoperative Pain
CountriesUnited States
CollaboratorsPremier Research
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartMar 2011
Primary CompletionJun 2011
TodayJul 2026
First PostedOct 19, 2010
Enrollment StartMar 22, 2011
Primary CompletionJun 20, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.7 years ago
Interventions
5x5cm bupivacaine collagen spongesdrug